Sibutramine: its mode of action and efficacy

被引：52

作者：

Finer, N ^{[1
]}

机构：

[1] Addenbrookes Hosp, Clin Res Facil, Cambridge CB2 2QQ, England

来源：

INTERNATIONAL JOURNAL OF OBESITY | 2002年 / 26卷 / Suppl 4期

关键词：

sibutramine; mechanism of action; weight loss; predictors of success;

D O I：

10.1038/sj.ijo.0802216

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sibutramine has a dual mode of action. It reduces food intake and attenuates the fall in metabolic rate associated with weight loss. The drug's neurochemical actions can also be distinguished from those of previous centrally acting anti-obesity agents. Clinical trials show that two out of three patients taking sibutramine lose greater than or equal to 5% weight and that the drug can enhance the maintenance of weight loss. Early weight loss predicts long-term success and can be used to guide clinical practice. To maximize the benefits of sibutramine, it is important that patients receive adjunctive diet and lifestyle therapy.

引用

页码：S29 / S33

页数：5

共 20 条

[1] Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine [J].

Apfelbaum, M ;

Vague, P ;

Ziegler, O ;

Hanotin, C ;

Thomas, F ;

Leutenegger, E .

AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :179-184

[2] When, for whom and how to use sibutramine? [J].

Astrup, A ;

Toubro, S .

INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (Suppl 4) :S2-S7

[3] Sibutramine produces dose-related weight loss [J].

Bray, GA ;

Blackburn, GL ;

Ferguson, JM ;

Greenway, FL ;

Jain, AK ;

Mendel, CM ;

Mendels, J ;

Ryan, DH ;

Schwartz, SL ;

Scheinbaum, ML ;

Seaton, TB .

OBESITY RESEARCH, 1999, 7 (02) :189-198

[4] Modalities of the food intake-reducing effect of sibutramine in humans [J].

Chapelot, D ;

Marmonier, C ;

Thomas, F ;

Hanotin, C .

PHYSIOLOGY & BEHAVIOR, 2000, 68 (03) :299-308

[5] WEIGHT-LOSS REDUCES THE RISK FOR SYMPTOMATIC KNEE OSTEOARTHRITIS IN WOMEN - THE FRAMINGHAM-STUDY [J].

FELSON, DT ;

ZHANG, YQ ;

ANTHONY, JM ;

NAIMARK, A ;

ANDERSON, JJ .

ANNALS OF INTERNAL MEDICINE, 1992, 116 (07) :535-539

[6] Sibutramine in clinical practice [J].

Finer, N .

INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (Suppl 4) :S12-S15

[7] Thermogenic effects of sibutramine in humans [J].

Hansen, DL ;

Toubro, S ;

Stock, MJ ;

Macdonald, IA ;

Astrup, A .

AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (06) :1180-1186

[8] The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction [J].

Hansen, DL ;

Toubro, S ;

Stock, MJ ;

Macdonald, IA ;

Astrup, A .

INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (10) :1016-1024

[9] Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity.: Results from the European multi-centre STORM trial [J].

Hansen, DL ;

Astrup, A ;

Toubro, S ;

Finer, N ;

Kopelman, P ;

Hilsted, J ;

Rössner, S ;

Saris, WHM ;

Van Gaal, LF ;

James, WPT ;

Goulder, M .

INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (04) :496-501

[10] Effect of sibutramine on weight maintenance after weight loss:: a randomised trial [J].

James, WPT ;

Astrup, A ;

Finer, N ;

Hilsted, J ;

Kopelman, P ;

Rössner, S ;

Saris, WHM ;

Van Gaal, LF .

LANCET, 2000, 356 (9248) :2119-2125

← 1 2 →